ReviewClinical reviews in allergy & immunology2026
Therapeutic Potential of Tulisokibart and Anti-TL1A Therapy in Inflammatory Disorders: Current Insights and Future Directions.
Review in Clinical reviews in allergy & immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circulating levels of TL1A and its decoy receptor DcR3 in systemic sclerosis.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor-like cytokine 1 A (TL1A), encoded by the TNFSF15 gene, is expressed on multiple cells, including endothelial cells and dendritic cells, and in a soluble form in serum. Due to its central role in regulating immune response, TL1A has been implicated in the pathogenesis of several autoimmune inflammatory diseases such as inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis (RA). Mechanistically, TL1A exerts proinflammatory effects through binding of death receptor 3 (DR3) to activate downstream signalling cascades that drive inflammation and apoptosis. Tulisokibart, a novel humanized anti-TL1A monoclonal antibody, has garnered significant attention following phase 2 clinical trials demonstrating robust efficacy in IBD. Additional anti-TL1A drugs, afimkibart and duvakitug, are progressing rapidly through clinical development pipeline across multiple indications, underscoring the broad therapeutic potential of TL1A blockade. This review delineates the pathomechanistic basis of anti-TL1A therapies and explores emerging clinical applications. Moreover, to facilitate precision medicine approaches and optimize therapeutic outcomes among different population subgroups, we analyse the potential impact of genetic polymorphisms on individual responses to TL1A-targeted therapy. Taken together, anti-TL1A therapies hold considerable promise for modulating adaptive and immune pathways and represent an innovative strategy for treating complex inflammatory diseases.
Indexed as
Identifiers
41904333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.